A study for effectiveness and safety of tocilizumab therapy in rheumatoid arthritis patients with renal insufficiency.

A study for effectiveness and safety of tocilizumab therapy in rheumatoid arthritis patients with renal insufficiency. - Tocilizumab for rheumatoid arthritis patients with renal insufficiency

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014934

Enrollment

400

Registered

2014-08-25

Start date

2014-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients with rheumatoid arthritis who were treated with tocilizumab in participating hospitals.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Changes in CDAI values after the 24-week treatment with tocilizumab	—

Secondary

Measure	Time frame
Improvement of anemia after the 24-week treatment with tocilizumab	—

Countries

Japan

Contacts

Public ContactShinji Furukawa

NHO Kumamoto Saishunsou National Hospital Secretariat

8211sy01@hosp.go.jp81-96-242-1000

Outcome results